Else Nutrition Holdings Inc (BABY)

Else Nutrition Announces CSE Conditional ApprovalJune 29, 2026 7:30 AM
PR Newswire (Canada) VANCOUVER, BC, June 29, 2026 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) (the "Company") is pleased to announce that it has received conditional approval to list its common shares on the Canadian Securities Exchange (the "CSE"). In connection with the conditional listing, the Company is working to complete an additional funding of US$310,000 with Lind Global Fund III LP.  Listing on the CSE also remains subject to the approval of the CSE and the satisfaction of customary listing conditions, and there can be no assurance that such listing will be obtained.In connection with the listing on the CSE, the Company will complete a share consolidation on the basis of 10 existing shares for each 1 new share. In addition the Company will settle $207,000 of debt by issuing common shares at a post-consolidated price of $0.15 per share. The Company is targeting a trading date of July 7 for the commencement of trading on the CSE, subject to meeting completing final filings with the CSE, and completing the above noted financing, debt settlement and the share consolidation.About Else Nutrition Holdings Inc. Else Nutrition Holdings Inc. is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth.Awards and Recognition:"2017 Best Health and Diet Solutions" award at Milan's Global Food Innovation Summit#1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler Formula Category"Best Dairy Alternative" Award 2021 at World Plant-Based ExpoNexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle categoryDuring September 2022, Else Super Cereal reached the #1 Best Seller in Baby Cereal across all brands on AmazonFor more information, visit www.elsenutrition.com or @elsenutrition on Facebook and Instagram.Neither the TSX nor its regulation services provider (as that term is defined in the policies of the TSX) accept responsibility for the adequacy or accuracy of this release.Caution Regarding Forward-Looking StatementsThis press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the Company's application to list its common shares on the CSE, the receipt of approval of the CSE listing application, obtaining funding from Lind Global Fund III LP, the continued trading of the Company's common shares and warrants on the TSX pending such listing, and the delisting of the Company's common shares and warrants from the TSX. Such forward-looking statements reflect current estimates, beliefs, and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Actual results may differ from the estimates, beliefs, and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. View original content to download multimedia:https://www.prnewswire.com/news-releases/else-nutrition-announces-cse-conditional-approval-302812798.htmlSOURCE Else Nutrition Holdings Inc. Original: Else Nutrition Announces CSE Conditional Approval

Else Nutrition kicks off a Manufacturing Drive in Q2 2026June 1, 2026 7:45 AM
PR Newswire (US) Expects to improve product supply
and meet growing consumer demand in the US and CanadaVANCOUVER, BC, June 1, 2026 /PRNewswire/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) ("Else" or the "Company"), a pioneer in whole food, Plant-Based nutrition for babies, toddlers, children and adults, is happy to announce that it is starting a manufacturing drive to meet growing US and Canadian consumers' demand. Dealing with cash constraints on one side, growing US consumers' demand on the other, and with the fast recovery of our Canadian retail business, we have struggled in the last year to produce enough stock to meet demand, and faced several Out-Of-Stock (OOS) situations that hurt our revenue and delayed our growth.We are happy to inform that we are now able to initiate a manufacturing drive that will allow us to keep in stock through the summer of 2026 in both the US and Canada. We plan to continue this drive through this summer and secure stock for the remainder of the year."I am very happy that we can launch a manufacturing drive and avoid OOS," said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. "It will allow us to support the growing demand for our products in the US and the re-launch of our products in Canada. Having sufficient products to meet the growing consumer demand will allow us to return to growth and reach our profitability goals."To delve deeper into Else Nutrition's offerings and its revolutionary approach to nutrition, visit www.elsenutrition.comAbout Else Nutrition Holdings Inc.Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL) is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and Plant-Based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, Plant-Based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth.Awards and Recognition:"2017 Best Health and Diet Solutions" award at Milan's Global Food Innovation Summit#1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler Formula Category"Best Dairy Alternative" Award 2021 at World Plant-Based ExpoNexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle categoryDuring September 2022, Else Super Cereal reached the #1 Best Seller in Baby Cereal across all brands on AmazonTSXNeither the TSX nor its regulation services provider (as that term is defined in the policies of the TSX) accept responsibility for the adequacy or accuracy of this release.Caution Regarding Forward-Looking StatementsThis press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs, and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID-19 and that the manufacturing, broker, and supply logistic agreement with the company does not terminate. Actual results may differ from the estimates, beliefs, and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. View original content to download multimedia:https://www.prnewswire.com/news-releases/else-nutrition-kicks-off-a-manufacturing-drive-in-q2-2026-302786749.htmlSOURCE Else Nutrition Holdings Inc. Original: Else Nutrition kicks off a Manufacturing Drive in Q2 2026

Upcoming Meeting Dates - May 25, 2026May 25, 2026 12:00 AM
NewsfileToronto, Ontario--(Newsfile Corp. - May 25, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies through the service of CDS Clearing and Depository Services Inc.Company NameRecord DateMeeting DateType Apex Critical Metals Corp. June 8, 2026July 10, 2026AG  Ashley Gold Corp. June 9, 2026July 14, 2026AS  Athena Gold Corporation June 9, 2026July 24, 2026AS  CORE SILVER CORP. *May 12, 2026June 16, 2026AGS Canasil Resources Inc. June 12, 2026July 21, 2026AGS EVERYDAY PEOPLE FINANCIAL CORPJune 8, 2026July 23, 2026AS  Else Nutrition Holdings Inc. May 20, 2026June 30, 2026AG  FTI Foodtech International Inc*May 19, 2026June 25, 2026A  Fluent Corp. June 12, 2026July 28, 2026AS  Forsys Metals Corp %May 22, 2026June 30, 2026AGS Future Fuels Inc. June 9, 2026July 14, 2026AG  GINSMS Inc. May 26, 2026June 26, 2026AS  Information Services CorporationMay 27, 2026June 26, 2026S  Matachewan Consolidated Mines *May 26, 2026June 30, 2026AG  Metasphere Labs Inc. *May 27, 2026July 9, 2026AS  Mineros S.A. June 1, 2026July 13, 2026S  Netramark Holdings Inc June 5, 2026July 13, 2026AGS NorthStar Gaming Holdings Inc.%April 10, 2026May 25, 2026AS  Omega Pacific Resources Inc. June 9, 2026July 15, 2026A  Orecap Invest Corp. May 29, 2026July 14, 2026AGS Playgon Games Inc. May 25, 2026June 29, 2026AGS Pulsar Helium Inc. June 12, 2026July 17, 2026AGS  Rakovina Therapeutics Inc. *July 7, 2026August 18, 2026AG  Roland Mineral Enterprises CorpJune 9, 2026July 14, 2026AS  SAPUTO INC June 12, 2026August 7, 2026A  Sabio Holdings Inc. *May 13, 2026July 10, 2026AG  Sable Resources Ltd. June 8, 2026July 14, 2026AS  Sankamap Metals Inc. June 9, 2026July 15, 2026A  Skull Ridge Gold Corp. June 12, 2026July 22, 2026AGS Stardust Metal Corp. June 1, 2026July 14, 2026AGS TOTAL TELCOM INC June 15, 2026July 17, 2026AG  Torrent Gold Inc. June 11, 2026July 17, 2026A  Uranium Royalty Corp June 15, 2026July 20, 2026S  VISION MARINE TECHNOLOGIES INCMay 15, 2026June 15, 2026S  Verses AI Inc. %April 24, 2026June 10, 2026A  Viridian Metals Inc. May 15, 2026June 22, 2026AS  Vitality Products Inc. June 11, 2026July 21, 2026AG  Volta Metals Ltd. June 10, 2026July 15, 2026AGS Xigem Technologies Corp. *May 19, 2026June 30, 2026AGS Legend:* = Change in Previously Reported Information
% = Cancelled Meeting
@ = Adjourned MeetingType of MeetingA = Annual Meeting
S = Special Meeting
G = General Meeting
B = Bondholder Meeting
C = Court Meeting For more information, please visit https://www.cds.ca/ To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298384 Original: Upcoming Meeting Dates - May 25, 2026

Else Nutrition Reports First Quarter 2026 Results Highlighting Significant Improvement in Gross Margin and Reduced Net LossMay 15, 2026 1:44 PM
PR Newswire (US) VANCOUVER, BC, May 15, 2026 /PRNewswire/ - ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) ("Else" or the "Company"), today reported financial results for the 2026 first quarter ended March 31, 2026, all figures are in CAD unless otherwise indicated. The financial statements and MD&A are available on SEDAR under the Company's profile. "During the first quarter of 2026, we remained intensely focused on strengthening the operational foundation of the business while navigating a challenging capital markets and retail environment," said Hamutal Yitzhak, Chief Executive Officer of Else Nutrition. "While revenue declined for the quarter to $1.5 million compared to $2.1 million in the prior-year parallel period mainly due to out-of-stock (OOS) challenges, our operational initiatives resulted in a significant improvement in profitability metrics and overall cost structure. Gross margin improved to 40% compared to 24% in the first quarter of 2025, reflecting the benefits of inventory optimization, tighter supply chain management, and disciplined operational execution. We are working diligently to produce more products, to reduce and eventually eliminate the damaging OOS situations, yet our production capabilities depend on our free cash position.""We also significantly reduced our quarterly net loss to $ 0.6 million, compared to $3.4 million in the same period last year, while dramatically reducing the operating expenses by 45% to $1.2 million from $2.2 million in the prior year period. These results demonstrate the impact of the restructuring and efficiency initiatives we have implemented over the past year, including streamlining lower-margin activities and optimizing marketing spend.""Importantly, we continue to see a growing demand for our products, and our belief in the long-term opportunity for clean-label, plant-based nutrition products is strengthening. Consumer awareness around dairy-free, minimally processed and sustainable nutrition solutions continues to expand globally, and Else remains uniquely positioned with differentiated products developed specifically for infants, toddlers, children, and for adults. We believe our proprietary formulations and plant-based platform continue to provide a strong foundation for future growth opportunities across multiple markets and channels. We understand that AI changes how consumers search for solutions, and we are working hard to adapt to this changing environment.""We also continue to work closely with the U.S. Food and Drug Administration and other regulatory authorities to advance our infant formula product toward commercialization. Advancing our infant formula through the regulatory process remains a key strategic priority for the Company, and we remain committed to supporting all required clinical, scientific, and regulatory activities necessary to bring this important product to market. We believe the infant formula category represents a significant long-term opportunity for Else and an important extension of our plant-based nutrition platform.""Management remains highly focused on maintaining trading continuity and preserving access to the public markets for our shareholders. While we continue to make every effort to maintain our current TSX listing, management is acting cautiously and diligently and is pursuing in parallel a listing on the Canadian Securities Exchange to help ensure market continuity for the benefit of our shareholders. We believe applying for a CSE listing represents an important step toward supporting continued liquidity and operational flexibility while we execute on our strategic priorities. Although the TSX delisting process has presented additional challenges, we remain focused on advancing the business, strengthening our financial position, and continuing to build long-term value around our differentiated plant-based nutrition platform.""Looking ahead, our priorities remain centered on disciplined execution, strategic partnerships, operational efficiency and strengthening the Else brand as we continue working to create long-term value for shareholders and advance our mission of delivering innovative plant-based nutrition products to families worldwide," concluded Ms. Yitzhak.2026 First Quarter Financial Results
All figures are in CAD unless otherwise indicated.Revenue for the three months ended March 31, 2026 was $1.5 million, compared to $2.1 million in the first quarter of 2025.Operating expenses for the quarter were $1.2 million, compared to $2.2 million in the first quarter of 2025.Gross profit for the first quarter of 2026 was $0.6 million (40%), compared to $0.5 (24%) million in the comparable prior-year quarter.Cash balance as of March 31, 2026, was $245 thousand dollars, including restricted cash.About Else Nutrition Holdings Inc.Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL) is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth.Awards and Recognition:"2017 Best Health and Diet Solutions" award at Milan's Global Food Innovation Summit#1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler Formula Category"Best Dairy Alternative" Award 2021 at World Plant-Based ExpoNexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle categoryDuring September 2022, Else Super Cereal reached the #1 Best Seller in Baby Cereal across all brands on AmazonIn May 2024 Else Nutrition's Ready-to-Drink Kids Vanilla Shake Named Among the Best in Family-Friendly Products by the Prestigious Mom's Choice Awards®TSXNeither the TSX nor its regulation services provider (as that term is defined in the policies of the TSX) accept responsibility for the adequacy or accuracy of this release.Caution Regarding Forward-Looking StatementsThis press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs, and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID-19 and that the manufacturing, broker, and supply logistic agreement with the company does not terminate. Actual results may differ from the estimates, beliefs, and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. View original content to download multimedia:https://www.prnewswire.com/news-releases/else-nutrition-reports-first-quarter-2026-results-highlighting-significant-improvement-in-gross-margin-and-reduced-net-loss-302773793.htmlSOURCE Else Nutrition Holdings Inc. Original: Else Nutrition Reports First Quarter 2026 Results Highlighting Significant Improvement in Gross Margin and Reduced Net Loss

Else Nutrition Commends Trump Administration's Expanded Commitment to Bolstering Infant Formulas Regulation in FY2027April 15, 2026 7:30 AM
PR Newswire (US)

President's Budget requested significant FDA funding increases, signaling growing support for Else's next-generation plant-based infant formulaBuilds Upon FY26 Congressional Appropriations Directive Report Language to Implement and Modernize Guidance for Plant-Based, Non-Soy, Non-Dairy Infant FormulasVANCOUVER, BC, April 15, 2026 /PRNewswire/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) ("Else" or the "Company"), a pioneer in whole-food plant-based, non-soy, non-dairy nutrition for early childhood and adult nutrition, today commended recent actions by the Trump Administration and the U.S. Food and Drug Administration (FDA) that signal increasing support for innovation and modernization within the infant formula market.







The President's Budget request for Fiscal Year 2027 reinforces funding for infant formula modernization through the FDA's Human Foods Program, including a proposed increase of approximately $108.5 million compared to the FY2026 enacted level. This requested increase, which was announced in early April 2026, identifies infant formula regulation as a key investment area within this program, reflecting growing institutional prioritization.Else believes this increased funding will expand FDA resources—including dedicated infant formula personnel, expertise, and research capabilities—to help advance modernization efforts such as finalizing Protein Efficiency Ratio (PER) guidance and clinical validation pathways, while enabling broader investments to strengthen the nation's infant formula supply. This intention coincides with the FY26 Congressional appropriations directive report language, which encourages the FDA to implement and modernize guidance for plant-based, non-soy, non-dairy infant formulas; an area where Else is uniquely positioned as a pioneer.Further supporting this momentum, infant formula has also been included among the FDA Human Foods Program's Priority Deliverables for 2026, demonstrating increased regulatory attention and potential pathway clarity for next-generation formulations. In addition, the FDA recently indicated that updated regulatory guidance on Protein Efficiency Ratios (PER) is expected to be finalized in 2026. While final guidance has not yet been released, the agency's decision to revisit PER standards represents an encouraging step toward enabling broader innovation and modernization across the category, particularly for alternative protein sources."We are highly encouraged by the Administration's continued focus on modernizing the regulatory framework for infant formula and advancing innovation in this critical category, as part of Operation Stork Speed," said Hamutal Yitzhak, Chief Executive Officer and Co-Founder of Else Nutrition. "These developments reflect a growing recognition of the need for more diverse, high-quality nutritional options, including plant-based alternatives. As a company dedicated to redefining infant and children's nutrition, we believe these efforts will help create a more supportive environment for innovation and ultimately expand access to safe, nutritious choices for families."Else believes that the evolving regulatory landscape, including initiatives such as Operation Stork Speed and increased FDA prioritization, has the potential to unlock new opportunities across the infant nutrition market. The Company continues to monitor these developments closely and remains engaged in supporting regulatory progress that aligns with its mission to deliver clean, sustainable, and nutritionally complete products.Else expects to provide further updates as these regulatory initiatives continue to evolve.About Else Nutrition Holdings Inc.Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL) is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and Plant-Based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, Plant-Based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth.Awards and Recognition:"2017 Best Health and Diet Solutions" award at Milan's Global Food Innovation Summit#1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler Formula Category"Best Dairy Alternative" Award 2021 at World Plant-Based ExpoNexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle categoryDuring September 2022, Else Super Cereal reached the #1 Best Seller in Baby Cereal across all brands on AmazonTSXNeither the TSX nor its regulation services provider (as that term is defined in the policies of the TSX) accept responsibility for the adequacy or accuracy of this release.Caution Regarding Forward-Looking StatementsThis press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs, and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID-19 and that the manufacturing, broker, and supply logistic agreement with the company does not terminate. Actual results may differ from the estimates, beliefs, and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.



View original content to download multimedia:https://www.prnewswire.com/news-releases/else-nutrition-commends-trump-administrations-expanded-commitment-to-bolstering-infant-formulas-regulation-in-fy2027-302742255.htmlSOURCE Else Nutrition Holdings Inc.

Original: Else Nutrition Commends Trump Administration's Expanded Commitment to Bolstering Infant Formulas Regulation in FY2027

Agree with your comment, However, one better play with many thousands share to make a few $$$ now and then. Our CEO is a dumb selfish idealistic incompetent person. She will go bancrupt or die before he ego accept defeat.

Even FDA approval won't bail BABY out. Only salvation will be a takeover/buyout by a whale needing a vegan formula.
IMO
In the meantime trade for a few bucks profit.

buying a few!
MT Newswires
07:30 AM EDT, 03/10/2026
Else Nutrition Expects To Benefit From FDA Regulatory Progress On Infant Formula Protein Standards
+12.50%
07:30 AM EDT, 03/10/2026 (MT Newswires) -- ELSE NUTRITION (BABY.TO), a pioneer in whole-food plant-based, non-soy, non-dairy nutrition for early childhood nutrition, noted Tuesday that the U.S. Food and Drug Administration (FDA) has formally listed Protein Efficiency Ratio (PER) Rat Bioassay Study Guidance as an active topic within its Foods Program regulatory agenda.

The company in a statement said the FDA's advancement of PER guidance represents a "meaningful step toward regulatory clarity for novel infant formulas, particularly plant-based formulations". It added: "Clearer scientific expectations for demonstrating protein quality are expected to reduce regulatory uncertainty and strengthen the pathway for potential FDA clearance of Else's plant-based infant formula in the United States."

In summary, ELSE said the updated FDA framework bolsters the scientific validation pathway for its plant based formula and accelerates U.S. commercialization potential.

Shares in ELSE eased to 52 week lows at $0.07 in Canada yesterday.

I TOUGHT THAT FOR A LONG TIME BUT FOR AS LONG AS OUR CEO CAN SELL NSHARES FOR HER PERSONAL FINANCING, SHE WILL KEEP THIS ALIVE IF SHE CAN KEEP ISSUING THE REMAINING SHARES IF SHE CAN GET BUYERS.

the only salvation is buy out. otherwise : toast

https://www.lemonde.fr/en/environment/article/2026/01/30/nestle-knew-of-toxins-in-baby-formula-10-days-before-first-recalls_6749964_114.html

''the share consolidation complete looks like the price is being raised to do a financing'' and ''good lawyer could easily win a lawsuit using this argument'' ...
1- We have an opprtunity with what seems to be a relatively great products offering (Thanks to our CEO).
HOWEVER
2- Financing and laesuits may (???) help extending the life of the company to help our CEO financed herself for somewhat longer
3- Unless products sell and create REVENUES and PROFITS the company will finish in a bancrupcy.
The issue:
OUR CEO BELIEVES MARKETING,
1- is an IRRECUPERABLE EXPENSE instead of
2- is a MANDATORY INVESTMENT if the market is to find and accept our offerings.
That philosophy will make her be bancrupt that is for sure ... unless she somehow accept that before it is to late (assuming we are not yet there already)

I would like to be wrong but I personally wrote off this bet because our CEO is so stubborn that she prefer to see the company fail than admit that even if she may be a great scientist she cannot accept that she also is a totally incompetent business manager. She is a dreamer and I beleive that even if her plant based formula providing superior health benefits in animal was to be recognized by the industry, she would keep believing that understanding what marketing is all about is useless and great products do sell by themselves.
Proof has often been made that procuct is HALF THE STORY and Marketing is THE OTHER HALK. The best example that I saw was the BETA fight (much better product) vs VHS (much less interesting products characteristics but great marketing strategies). The best product fails crushed by a better marketing strategy.
Our CEO refuses to acknowledge that, the company she left as a researcher frustrated her by not focussing enough on ''her'' products but spending a lot on marketing.
I personally do not believe she will ever be humble enough to recognise that and that is why I do not expect my bet to be recuperated under her leadership. To bad but that what runs into sometime betting on an OTC type stock.

I also hope to be wrong but believe our CEO is not smart enough to figure out what is going on and worst even, smart enough to get somequalified help.

With the share consolidation complete looks like the price is being raised to do a financing at least it's not being done at the recent lows.

I am not a fan of raising capital through brokers as they have way to much influence on companies... Rights offerings are the best way to raise capital in my opinion and honestly public companies should be forced to do rights offerings only to raise capital and if shareholders do not want to exersize their rights then they can sell them to other investors in to public market. This is the only way to ensure the fiduciary relationship is not breached in my opinion with they original investors which I believe is breached when new investors are granted rights to financing options over preexisting shareholders; I think a good lawyer could easily win a lawsuit using this argument and make a name for him or herself.

You're saying what we are all thinking, but we're hoping you're somehow wrong...


Ultimately we need to see a marketing campaign centered around proof that a plant based formula provides superior health benefits in animal studies to solidify it as a viable alternative to other traditional formulas to create confidence in purchasers then this product would soar.

Personally I would do studies on rats and small mammals using else's formulas and prove equal to superior results versus traditional formulasand then create a marketing campaign around that information.

now known as babyf )-;

And $0,10 after a 10:1 R/S. I wonder if our CEO still work or just try to sell shares to pay her grossery.

babyf is now 290257104
ELSE NUTRITION HLDGS INCCOM NEW

The incompetent woman is only dealing in shares, regularly issuing some to finance her own personal obligations but she cannot create anything worth mentionning from her ''pet shop'' like company. She doesn't even have the smarts required to realise she need to put someone having the skills required to MAYBE do something out of the ashes created by our current incompetent CEO.
With new shares at 15 cents, she will now be more able to dilute shareholders

BABYF: effective Nov 6,2025 a one for 10 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

reverse split!!!!!!!!!!!!!!!!!!!

Once again, notwithstanding the past experience, management doesn't recognise failure to grow sales, is proud to reduce costs, proud to say advertizing (already negligeable) was cost in half, ... Never heard that an incompetent analysis of a desesperate situation.
Question period is based on self developped meaningless questions.
Till management is replaced or the company is sold, this stock will keep being worthless most likely endingup being delisted altogether.
Conclusion comments is made of meaningless garbage, repetition of the same topics and once again not do not even mention words such as Marketing, Advertizing or sales.
Incompetence at its best.

Once more, the company does focus on products and financials but obviously does not believe in Marketing aimed at making potential customers aware of our offerings and their characteristics. For our CEO, morketing is limited to placing boxes on shelves HOPING potential clients will buy something they know nothing about. Our CEO seems to be doing a good job at R&D, manufacturing and placing boxes on shelves but she keeps proving that she believes marketing is a useless expense. If I remember well that is the reason she did quit her previous imployment in a company she tought was focussed on marketing and selling instead of R&D and manufacturing. Years later, non withstanding her almost failure experience, she stubbornly keep believing to be right keeping her proven wrong belief.

2025 First Quarter Financial Results
All figures are in CAD unless otherwise indicated.
• Revenue for the first quarter of 2025 was $2.1 million, the same level as the first quarter of 2024.
• Operating expenses for the first quarter of 2025 were $2.2 million, a decrease of 48% compared to $4.2 million for the first quarter of 2024.
• Gross profit for the first quarter of 2025 increased to $0.5 million, compared to $0.18 million for the first quarter of 2024.
• Gross profit margin for the first quarter of 2025 increased significantly to 25%, compared to 8% in the first quarter of 2024.
• Cash balance as of March 31, 2025, was $0.2 million (including restricted cash).
• "As we entered 2025, we continued reshaping Else Nutrition—implementing strategic changes essential to long-term success," commented Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. "Despite the lingering headwinds from 2024, we held revenue steady while significantly reducing operating expenses and driving a sharp improvement in gross profit. We are now operating with more discipline, sharper focus, and growing confidence in our direction. We've made tough but necessary decisions to realign our structure and eliminate inefficiencies, allowing us to protect core capabilities and build a more resilient foundation."
• "Operationally, a major milestone is our planned shift toward manufacturing powder formulas in Europe. This initiative will allow us to reduce production costs, improve gross margins, and better control inventory and logistics. This geographic diversification is a key part of mitigating supply chain risks, navigating tariffs, and strengthening the reliability of our product delivery. On the commercial front, we reevaluated our retail distribution model and rebalanced it to focus on higher-potential partnerships- supported by a more targeted, data-driven go-to-market approach."
• "On the regulatory front, we remain deeply committed to advancing access to plant-based infant nutrition. The launch of Operation Stork Speed and the advancement of the FY2026 Agriculture Appropriations Bill mark pivotal progress in modernizing U.S. policy around infant formula. These efforts support streamlined FDA approval pathways and expanded access to clean-label, non-dairy, non-soy alternatives—needs that have long gone unmet. We are optimistic that this evolving landscape will pave the way for clinical trials of our infant formula and help close a critical gap for families seeking trusted, science-based alternatives."
• "The remainder of 2025 will be an important period as we continue to implement the changes necessary to strengthen the business. We are focused on deepening our retail partnerships, expanding our global manufacturing capabilities, and driving growth across our core product categories. We are also exploring select strategic collaborations that align with our mission and can accelerate our path to scale. As we continue executing our transformation, our commitment remains clear: to deliver clean, innovative nutrition solutions to more families around the world while building a stronger, more agile business for the long term."
• Conference Call
• Else Nutrition management plans to host a business update conference call today at 10:00 a.m. Eastern Time to discuss the Company's financial results for the first quarter of 2025 ended March 31, 2025, as well as the Company's corporate progress and other developments.
• The conference call will be available via telephone by dialing toll free 1-877-407-9219 for U.S. callers or +1-412-652-1274 for international callers. A webcast of the call may be accessed at https://event.choruscall.com/mediaframe/webcast.html?webcastid=f7UwQpaT or on the Investor Relations section of the Company's website at https://investors.elsenutrition.com/.
• A webcast replay will be available on the Investor Relations section of the Company's website (https://investors.elsenutrition.com/), through August 21, 2026. A telephone replay of the call will be available approximately three hours following the call, through September 3, 2025, and can be accessed by dialing 1-877-660-6853 for U.S. callers or +1-201-612-7415 for international callers and entering conference ID: 13755545.
• To delve deeper into Else Nutrition's offerings and its revolutionary approach to kids' nutrition, visit www.elsenutrition.com
Awards and Recognition:
• "2017 Best Health and Diet Solutions" award at Milan's Global Food Innovation Summit
• #1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler Formula Category
• "Best Dairy Alternative" Award 2021 at World Plant-Based Expo
• Nexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle category
• During September 2022, Else Super Cereal reached the #1 Best Seller in Baby Cereal across all brands on Amazon
• In May 2024 Else Nutrition's Ready-to-Drink Kids Vanilla Shake Named Among the Best in Family-Friendly Products by the Prestigious Mom's Choice Awards®
TSX
Neither the TSX nor its regulation services provider (as that term is defined in the policies of the TSX) accept responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs, and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID-19 and that the manufacturing, broker, and supply logistic agreement with the company does not terminate. Actual results may differ from the estimates, beliefs, and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
• View original content to download multimedia:https://www.prnewswire.com/news-releases/else-nutrition-reports-2025-first-quarter-financial-results-and-provides-business-update-302535291.html

VANCOUVER, BC, Aug. 19, 2025 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) ("Else" or the "Company"), today announced that it plans to host a business update conference call at 10:00 a.m. Eastern Time on Thursday, August 21, 2025 to discuss the Company's financial results for the first quarter of 2025 ended March 31, 2025, as well as the Company's corporate progress and other developments.

VANCOUVER, BC, Aug. 1, 2025 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) (the "Company") announces that further to its news release dated June 19, 2025, the Toronto Stock Exchange has granted the Company a further extension to hold its annual general meeting of shareholders for 2025 (the "AGM"). The Company is now required to hold the AGM by September 30, 2025.

"ELSE NUTRITION ANNOUNCES DELAY IN FILING FINANCIAL STATEMENTS AND EXTENSION OF ANNUAL GENERAL MEETING OF SHAREHOLDERS"

https://fox59.com/business/press-releases/cision/20250619VA14519/else-nutrition-announces-delay-in-filing-financial-statements-and-extension-of-annual-general-meeting-of-shareholders/

*** Hilarious, and so predictable ***

ELSE NUTRITION ANNOUNCES DELAY IN FILING FINANCIAL STATEMENTS AND EXTENSION OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
2:24 PM ET 6/19/25 | Dow Jones

VANCOUVER, BC, June 19, 2025 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) (the "Company") announces that the Company's principal regulator in Canada, the British Columbia Securities Commission (the "BCSC"), has notified the Company that it has issued a cease trade order (the "CTO") under Multilateral Instrument 11-103 Failure-to-File Cease Trade Orders in Multiple Jurisdictions against the Company. The CTO was issued as a result of the Company's delay in filing its interim financial statements, the accompanying management discussion and analysis, and CEO and CFO certifications for the period ended March 31, 2025 (the "Interim Filings") on SEDAR+ within 45 days after the end of its interim period on March 31, 2025.

The CTO prohibits the trading by any person or company of any securities of the Company in each jurisdiction in Canada in which the Company is a reporting issuer, until such time as the Company is able to complete the filing of the Interim Filings and successfully apply for a revocation of the CTO. The CTO provides an exception for beneficial securityholders of the Company who are not currently (and were not as of June 16, 2025) insiders or control persons of the Company and who sell securities of the Company acquired before June 16, 2025, if both of the following criteria are met: (i) the sale is made through a "foreign organized regulated market", as defined in section 1.1 of the Universal Market Integrity Rules of the Investment Industry Regulatory Organization of Canada, and (ii) the sale is made through an investment dealer registered in a jurisdiction of Canada in accordance with applicable securities legislation.

The Company expects to file its Interim Filings by June 30, 2025 and will issue a news release once they have been filed.

Extension of Annual General Meeting of Shareholders

In addition, the Company announces that the Toronto Stock Exchange has granted the Company an extension to hold its annual general meeting of shareholders for 2025 (the "AGM"), which it was originally required to be held by June 30, 2025. The Company is now required to hold the AGM by July 31, 2025.

About Else Nutrition Holdings Inc.

Else Nutrition Holdings Inc. is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth.

Awards and Recognition:
-- "2017 Best Health and Diet Solutions" award at Milan's Global Food
Innovation Summit

-- #1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler
Formula Category

-- "Best Dairy Alternative" Award 2021 at World Plant-Based Expo

-- Nexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle
category

-- During September 2022, Else Super Cereal reached the #1 Best Seller in
Baby Cereal across all brands on Amazon

For more information, visit www.elsenutrition.com or @elsenutrition on Facebook and Instagram.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include but are not limited to, statements with respect to the Company filing its interim financial statements and MD&A. These forward-looking statements are made as of the date of this press release. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. Although the Company believes the forward-looking statements in this press release are reasonable, it can give no assurance that the expectations and assumptions in such statements will prove to be correct. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements. Such factors and assumptions include, among others, variations in market conditions; currency exchange rates; the Company's ability to obtain any necessary permits, consents or authorizations required for its activities; the Company's ability to access further funding, to continue its projected growth, or to be fully able to implement its business strategies. In addition, there are known and unknown risk factors which could cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/else-nutrition-announces-delay-in-filing-financial-statements-and-extension-of-annual-general-meeting-of-shareholders-302486531.html

SOURCE Else Nutrition Holdings Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/19/c2074.html

/CONTACT:

For more information, contact: Mrs. Hamutal Yitzhak, CEO, Co-Founder & Director, ELSE Nutrition Holdings Inc., E: hamutaly @; Investor Relations Contact: Alexandra Schilt, Crescendo Communications, LLC, Office: (212) 671-1020, Email: baby@crescendo-ir.com
Copyright CNW Group 2025


> Dow Jones Newswires

June 19, 2025 14:24 ET (18:24 GMT)

Bar, >> organic baby food <<

This still looks like an interesting niche area, so maybe these guys will have better luck (article below). Looks like heavyweights Goldman and JPM will be underwriting the IPO, so a good sign.

Else's over-reliance on buckwheat may have been a key mistake. While buckwheat is nutritious, the taste isn't great, and it's also high in lectins, which can irritate the GI tract. In contrast, Once Upon a Farm uses --> avocado, blueberry, coconut milk, flaxseed, ginger, kale, mango, pumpkin seed, spinach, sweet potato, strawberry, turmeric. Taste is the key to getting kids to love the product, and Else apparently came up way short in the taste department -


>>> Jennifer Garner's baby food company confidentially files for an IPO, sources say


Reuters

June 18, 2025

by Echo Wang and Abigail Summerville


https://finance.yahoo.com/news/jennifer-garners-baby-food-company-180711826.html


(Reuters) - Once Upon a Farm, the organic baby food company co-founded by actor Jennifer Garner, has filed confidentially for an initial public offering in New York, according to people familiar with the matter.

The Berkeley, California-based company has tapped a group of investment banks for the IPO, which could occur as soon as this year, said the sources, who cautioned that the plans could change, depending on market conditions. Goldman Sachs and JPMorgan are the lead underwriters, said the sources, who requested anonymity because the plans are confidential.

The offering could value the company at about $1 billion, one of the persons said. Once Upon a Farm did not immediately respond to a request for comment, Goldman Sachs and JPMorgan declined to comment.

Garner is known for her work in the TV drama "Alias" and films including "Dallas Buyers Club" and "Catch Me If You Can." A mother of three, she has said she cares deeply about childhood nutrition, and she grows some produce for Once Upon a Farm on her family's century-old farm in Oklahoma.

Once Upon a Farm was founded in 2015 by Cassandra Curtis and Ari Raz to create more nutritious baby-food options. In 2017, Garner and John Foraker, the former CEO of food brand Annie's, joined the company as co-founders.

The company's products for babies, toddlers and children range from oat bars to cold-pressed pouches and frozen meals, and they are sold in supermarkets across the U.S.

An IPO for the company would build on momentum for market debuts in the U.S., a sector that has lately thawed after the Trump administration's tariff announcements earlier this year cast a chill. So far this year, IPOs listed in the U.S. have raised about $27 billion, down from $41 billion in the same period last year, according to data compiled by Dealogic. But this year's figure is more than in 2022 and 2023, when IPOs raised $22 billion and $24 billion, respectively, over the same time frame, according to Dealogic.

In its Nasdaq debut last week, digital bank Chime jumped 59%, valuing the company at $18.4 billion. The stock of stablecoin issuer Circle Internet Group climbed to $103.75 and was halted several times for volatility during a wild first day of trading earlier this month.

<<<



---

Else Nutrition Applauds U.S. Government's Historic Shift in Infant Formula Rules, Unlocking Path to Commercialize the World's First Whole-Food, Dairy-Free Infant Formula
7:30 AM ET 6/10/25 | Dow Jones

Else Nutrition Welcomes 3 Major Federal Developments that Could Unlock Market Access & Open the Door to the First Major Breakthrough in Infant Formula in Decades

VANCOUVER, BC, June 10, 2025 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) ("Else" or the "Company"), a global leader in clean label, plant-based childhood nutrition, welcomes a recent trio of significant policy signals from the U.S. Government that could reshape the nation's infant formula landscape.

These developments - spanning FDA regulatory reform, Congressional oversight, and executive action - reflect growing national momentum to modernize outdated regulations and expand consumer choice in baby formula.

National Academy Report Supports Smarter Science, Aligns with Else's Regulatory Approach

In a move that could have broad implications for new formula entrants, the FDA commissioned a National Academy of Sciences study to examine global regulatory standards for infant formula - particularly focusing on the outdated Protein Efficiency Ratio (PER) study, which had long served as a barrier for plant-based options like Else's.

The newly released study recommends replacing the outdated PER test with modern, evidence-based alternatives that better reflect international norms and nutritional science. This marks a turning point for Else, whose regulatory strategy has been built around these same more progressive standards.

"We are encouraged by the Academy's findings and look forward to these recommendations informing forthcoming FDA guidance," said Hamutal Yitzhak, CEO & Co-Founder, Else Nutrition.

Congressional Pressure Grows for Modernized Plant-Based Infant Formula Pathway

In parallel, Else Nutrition welcomes mounting attention to infant formula policy from the United States Congress. Earlier this year, top Republican Appropriators - a Members of a powerful Committee in Congress that maintains the "Power of the Purse" - sent a formal Congressional Oversight letter to the agency, urging the FDA to create a clear, modernized regulatory pathway for plant-based infant formula that matches the international standard. Congress' intent reflects a shared perspective that the National Academy study unveiled.

This rare Congressional intervention emphasizes the urgency of reform and calls for U.S. policy to upgrade to international standards that already embrace plant-based options. It also signals the potential for future Congressional action to reinforce the need for change and hold the FDA accountable.

"Congressional Appropriators are sending a strong signal that American parents deserve safe, vetted plant-based alternatives, and that companies like Else deserve a fair, science-aligned path to market, with regulatory guidance to match," added Ms. Yitzhak.

Administration Launches 'Operation Stork Speed' to Cut Red Tape

Furthering the support is the Administration's new initiative, Operation Stork Speed, aimed at accelerating access to infant formula by streamlining regulatory processes and clearing bureaucratic roadblocks. The program is expected to fast-track FDA reforms while ensuring safety and nutritional integrity.

Else Nutrition looks forward to engaging directly with the Administration to help shape a smarter, more inclusive infant formula future.

A New Era of Opportunity for Infant Nutrition

Together, these three developments - scientific, legislative, and executive - signal a generational shift in how the U.S. regulates and supports infant nutrition. For Else Nutrition, they offer renewed confidence that the path forward is finally being cleared. This initiative is a direct complement to the Congressional attention and the National Academy study, and Else looks forward to collaborating with the Administration.

"These reforms aren't just good for Else - they're good for every parent seeking cleaner, safer, baby formula options beyond dairy," said Ms. Yitzhak. "We continually get requests from so many families in real need of finding an alternative beyond dairy-based baby formula. We're proud to be at the forefront of this movement for change and are ready to serve American families with the trusted nutrition they deserve."

Our researcher type CIO still hasn't figure out that she has been the problem all the way thru this other year. Because of her stobboness to try to run an operation she doesn't understand, he's heading right into a bancrupcy unless she finds competent help ... assuming she can even understand she need thad badly. I do not hold my breath.

Press Release: Else Nutrition Reports 2024 Fiscal Year Financial Results and Provides Business Update
1:12 PM ET 6/2/25 | Dow Jones

Conference call to be held Tuesday, June 3(rd) at 10:00 AM Eastern Time

VANCOUVER, BC, June 2, 2025 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) ("Else" or the "Company"), reported financial results for the 2024 fiscal year ended December 31, 2024. The financial statements and MD&A are available on SEDAR under the Company's profile.

"2024 was a defining year for Else Nutrition, marked by significant challenges that ultimately led to pivotal decisions shaping our future," commented Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. "While we encountered major headwinds, including funding constraints, inventory shortages, and a limited marketing budget, we took decisive actions to secure our future. Specifically, we optimized operations, significantly reduced overhead costs, and secured essential funding. We also streamlined our cost structure by cutting underperforming roles, reducing low-ROI marketing spend, and exiting unprofitable retail partnerships. In addition, we restructured R&D operations, including the closure of our Israel lab, to preserve innovation capacity while improving financial performance. Furthermore, we plan to expand our manufacturing and prepare our powder formula in Europe, which will lower production costs, improve margins, and enhance product quality."

"Despite our challenges, we made important progress including successfully launching our first Adult Ready-to-Drink (RTD) product, expanding retail placement for our Kids RTD product, and increasing our presence in the U.S. through e-commerce platforms. These milestones reflect the growing demand for plant-based, allergen-friendly nutrition, and we intend to capitalize on these opportunities."

"On the regulatory front, we are encouraged by the FDA and HHS's launch of Operation Stork Speed, an initiative aimed at expanding infant formula options and strengthening supply chain resilience. Through our continued bipartisan advocacy efforts, we aim to make significant progress toward modernizing FDA guidelines for plant-based, non-soy, non-dairy infant formula. We look forward to working closely with regulators to establish a clear pathway, ensuring that parents have access to safe, high-quality, and scientifically backed nutrition alternatives."

"Furthermore, we were recently featured in an op-ed published in The Washington Times, titled "Operation Stork Speed will ensure babies get the nutrition they need." The piece highlights the importance of accelerating access to clean-label, plant-based alternatives and aligns with our broader mission and ongoing advocacy efforts in Washington to promote science-backed updates to infant nutrition guidelines."

"Looking ahead to 2025, we are focused on expanding our retail distribution, scaling our European production, and enhancing brand visibility through targeted marketing and strategic partnerships. With a solid foundation in place, Else Nutrition is well-positioned for long-term growth, and we remain committed to delivering clean-label, plant-based nutrition solutions that meet the needs of families worldwide."

2024 Fiscal Year Financial Results

All figures are in CAD unless otherwise indicated.
-- Revenue for 2024 decreased approximately 14.8% to $8 million compared to
$9.4 million for 2023.

-- Operating expenses for 2024 was $13.6 million, a decrease of 20% compared
to $16.9 million for 2023

-- Cash balance as of December 31, 2024, was $0.3 million (including
restricted cash).

Conference Call

Else Nutrition management plans to host a business update conference call Tuesday, June 3(rd) at 10:00 a.m. Eastern Time to discuss the Company's financial results for the 2024 fiscal year ended December 31, 2024, as well as the Company's corporate progress and other developments.

The conference call will be available via telephone by dialing toll free 1-877-407-9219 for U.S. callers or +1-412-652-1274 for international callers. A webcast of the call may be accessed at https://event.choruscall.com/mediaframe/webcast.html?webcastid=vDEyPa8B or on the Investor Relations section of the Company's website at https://investors.elsenutrition.com/.

A webcast replay will be available on the Investor Relations section of the Company's website (https://investors.elsenutrition.com/), through June 3, 2026. A telephone replay of the call will be available approximately three hours following the call, through June 17, 2025, and can be accessed by dialing 1-877-660-6853 for U.S. callers or +1-201-612-7415 for international callers and entering conference ID: 13754118.

To delve deeper into Else Nutrition's offerings and its revolutionary approach to kids' nutrition, visit www.elsenutrition.com

About Else Nutrition Holdings Inc.

Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL) is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth.

Awards and Recognition:
-- "2017 Best Health and Diet Solutions" award at Milan's Global Food
Innovation Summit

-- #1 Best Seller on Amazon in the Fall of 2020 in the New Bab

BABYF is off something over 99+% since I began following this POS several years ago. Why did I follow it? Because I spotted it immediately as floorless, moat-less rubbish. Uniquely awful in several way.

Of course, I never bought any BABYF. My kids have large cap blue chips and index funds. Audited dividend payers.

If I have to go that far, my wife will get rid of what she call garbage stocvks (LOL)

pual, leave shares to grandkids and perhaps they'll reap the rewards > if any.

I enjoy following 2 small stocks of companies I betted on and traded years ago (getting my unit cost very negligeable). Both try to market great PRODUCTS/SERVICES but up to now, they are not having the success one should have expected out of them. In both case the founding CEO's are dedicated to be THE OWNER of their companies (majority shareholders) and both run the risk to run of of time because they miss ONE OF THE CRITICAL SUCCESS FACTORS (CSF) making companies succesful. One is a MARKETING DISASTER and the other one is a FINANCIALS MESS. They still can both succeed (otherwise I would have sold out) but both can go bancrupt unless they can stop being a one man/woman show. I therefore have a minimal exposure if they fail but a tremendous gain to get if they pull out of their mess before I die. FUTURE WILL TELL (LOL)

''Urgent Need for Infant Formula Alternatives'' ... according to who ?

''we look forward to continuing to collaborate with the White House, policymakers, and the FDA as we look to bring our unique solution to market in a swift and responsible manner."
Nothing wrong with that BUT ... She urgently needs help in MARKETING. She may be (is?) a GENIUS in the SCIENCES REQUIRED IN DEVELOPPING PRODUCTS but she has proven for years now that she is INCOMPETENT in the ART OF MARKETING.
She left her previous job in a very successful company not giving enough attention to ''scientific product developper'' and thereafter created a company focussed on product development but neglecting the art of marketing altogerther.
I cannot understand why she still stubornly refuses to see that this attitude made her a market failure for years.
I hope someone convince her to figure out what she keeps refuses to understand and accept.
SUCCESS REQUIRES BOTH MARKETING AND SCIENTIFIC SKILLS WORKING AS A TEAM (Having both skills in the same person is very exceptional and our CEO hasn't been granted this rare set of skills.
THE QUESTION: Will she accept that thruth or keep going till she fails for good ???

(PR) Else Nutrition CEO Highlights Urgent Need for Infant Formula Alternatives in The Washington Times Op-Ed
7:30 AM ET 5/28/25 | PR Newswire

VANCOUVER, BC, May 28, 2025 /PRNewswire/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) ("Else" or the "Company"), a pioneer in wholefood, Plant-Based nutrition for babies, toddlers, children and adults, is pleased to announce that its CEO and Co-Founder, Hamutal Yitzhak, authored a featured op-ed published in The Washington Times on May 25, 2025. Titled "Operation Stork Speed will ensure babies get the nutrition they need," the piece highlights the urgent need to modernize the infant formula regulatory environment and emphasizes the importance of increasing access to safe and innovative nutrition options--particularly for infants with dietary restrictions or allergen sensitivities. The Washington Times has a substantial readership in Washington, D.C., particularly among Congress and the Administration.

"Our mission has always been to deliver a safe, plant-based infant formula that supports healthy development and gives families--especially those with dietary or dairy/soy allergen concerns--greater access to trusted nutrition," said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. "Operation Stork Speed is an excellent initiative designed to expand access to these types of formulas, and as noted in the Washington Times op-ed, we look forward to continuing to collaborate with the White House, policymakers, and the FDA as we look to bring our unique solution to market in a swift and responsible manner."

Regulatory Pathway and Status

Else Nutrition has developed a clean-label, whole plant-based infant formula intended as an alternative to dairy- and soy-based products. In 2023, the Company successfully concluded the pre-clinical studies required and received Institutional Review Board (IRB) approval for its infant growth clinical study protocol--marking a key step toward U.S. Food and Drug Administration (FDA) compliance. At present, the Company is awaiting final authorization from the FDA to initiate its clinical trial in the United States, pending regulatory modernization that the company believes may be accelerated through Operation Stork Speed. Several Congressional Appropriators recently called on the FDA to accelerate this effort, as directed through an oversight letter.

Policy Advocacy and Operation Stork Speed

The op-ed coincides with the recent launch of Operation Stork Speed, an initiative by the Trump administration and Health and Human Services Secretary Robert F. Kennedy Jr., aimed at improving the regulatory review and safety of infant formula in the United States as well as encouraging innovation and transparency in formula composition to serve unmet needs. Ms. Yitzhak's commentary lends industry perspective to this national conversation and urges regulatory authorities to accelerate the path to market for scientifically supported, non-traditional formula options.

Else Nutrition is actively engaged in this effort through direct outreach to policymakers, bipartisan advocacy on Capitol Hill, and consumer education. The Company continues to advocate for updated infant formula guidelines that recognize the validity and safety of plant-based, non-soy, allergen-friendly alternatives.

About Else Nutrition Holdings Inc.

Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL) is a food an

Yes our problem (according to our CEO) was and still is the lack of shelves to store our procuct inventories. The fact that no one knows what is in these boxes is not an issue, everyone knows that doing her shopping, a mother of a baby does enjoy reading texts printed on boxes she never even noticed before. That renders our CEO ''Thrilled'' ???

Else Nutrition Expands Nationwide with Kids Ready-to-Drink Shakes in 1,000 Leading U.S. Retailer Stores
7:30 AM ET 5/27/25 | Dow Jones

VANCOUVER, BC, May 27, 2025 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) ("Else" or the "Company"), a leader in plant-based nutrition for early life and adult nutrition, is excited to announce its expanded footprint in the U.S. retail market with the launch of its Ready-to-Drink (RTD) products in a leading grocery retail chain. Starting May 2025, Else's clean-label Kids RTD products are available in 1,000 stores nationwide.

Launched in 2024, Else's ready-to-drink kids' shakes quickly gained traction among parents seeking nutritious, dairy-free, and soy-free options for their children.

"We are thrilled to see our RTD line gain a prominent spot on the shelves of this retail giant," said Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. "This milestone demonstrates the strength of the Kids RTD category and the increasing consumer demand for clean-label, plant-based options. Kids don't need another ultra-processed drink, and our minimally processed ingredients-based shakes are the only whole-food-based option that both parents and kids love."

To delve deeper into Else Nutrition's offerings and its revolutionary approach to kids' nutrition, visit www.elsenutrition.com

Never before (multi decades of experience) did I see a company having that level of potential (5 years ago) been that much mismanaged by an executive stupid enough to keep digging a hole she was getting into. Fortunately I traded early when the stock was swingning up and down daily (Net cost thereafter minimal) but I anyhow lost somewhat (nothing important however). What is frustrating is not the lost money but the destruction of a great opportunity by incompetence and mismanagement.

They manufacture somewhere in Ohio last I checked.
They did at one time mention opening a mfgr plant in Oregon.
I dk if that ever happened.

Cannot find info if Elise will also face Tariff issues,

May be she did, maybe she did not ... We may never know because her incompetence will have make the company fail. Bosh ... you win some, you lose some ... Selling the remaining shares at that pps would be ridiculous ...

Thanks for the post.

Bottom line I think is..... she doesn't have anything special here. 🤣

Let's not forget that the market these products are in is not incredibly large either. You are looking for a person who has a child, wants no diary or soy, the child tolerates the taste, and parents can afford these products. It's a niche market.

As you are aware, there are numerous vendors in the infant formula market. Always creating new products.

Take a look at this published paper recently (2025):

A Novel Infant Formula with Medium- and Long-Chain Triacylglycerols and sn-2 Palmitate Supports Adequate Growth and Lipid Absorption in Healthy Term Infants
https://www.mdpi.com/2072-6643/17/9/1401

Medium- and long-chain triacylglycerols (MLCTs) and sn-2 palmitate constitute approximately 70~80% of total breast milk fat. The structured lipid MLCTs and sn-2 palmitate, mimicking human milk, have demonstrated improvement in lipid absorption and energy metabolism in vitro and in animal experiments

Also, we can compare the difference in revenue in diary milk vs. all other "milk" alternatives for adults and see that the latter doesn't compare very much.

The average weekly sales of all dairy and plant-based milk products over the 2018-2022 years are $290 million. Average weekly sales of regular dairy milk are $219 million/week, accounting for the largest share of this category at 75.6% (Figure 1).

https://ag.purdue.edu/cfdas/wp-content/uploads/2023/07/An-Analysis-of-U.S.-Dairy-and-Non-Dairy-Milk-Demand_USB-approval_6-29-update.pdf

Changing the perception of people through thousands of years of drinking milk is one heck of a challenge.

With all that said, I have a hard time believing that she does not understand marketing a product. Even the most basic entrepreneur understands this.

Is she really not smart enough to grasp this? Is she really not smart enough to hire a firm to help her? Or a person with knowledge?

It seems way too unrealistic.

In all honesty, Tesla doesn't do advertising in the traditional sense and has no marketing budget. 🤣

Maybe it's just her way of doing business as well. Word of mouth. 🤣

THE ESSENCE OF THIS PR: Else needs access to more SHELVES

This new PR once more demonstrate the total incompetence of our CEO (At least in managing the company).
She effectively may be a great product conceptor and developer but she doesn’t have any idea of what is required to have products on shelves BOUGHT BY CONSUMERS.

Notwithstanding the disastrous past 5 years or so, once again our ridiculous CEO demonstrates that her belief is still that OUR PROBLEM is LACK OF AVAILABILITY OF SHELVES to store our products on. She writes: ‘’With public support and FDA cooperation, the Company can ‘’Bring its formula to american SHELVES’’. She adds: ‘’Modernizing regulatory pathways is the crucial next step so the Company can Bring its formula to American SHELVES’’.

HISTORY
4,5 years ago (2020-12-09) our share were selling at $4,26.
Since then, AFTER ADDING THOUSANDS OF SHELVES to stock our boxes on, it trades at $0,015 a 97% drop.

QUESTION
Can anyone explain to her that having access to more shells is not her problem but HAVING POTENTIAL CUSTOMERS BUY THE PRODUCT OFF THE SHELVES is the urgent priority that must be addressed ? Would be nice if someone was to inform the market of what is in these anonymous boxes !!!

It is my opinion based on facts and experience. Having time to lose today, let me prove it ...

After 5 years of believing that putting boxes on shelves will automatically make prospect to change their habits without knowing what these new boxes are all about was dumb and a demonstrated belief of our CEO (I said it in here for years).
The Executive team our CEO built was qualified to operate Lab, technical or research and even the one she made in charge of ‘’business development in a very specific competitive market ‘’previously was Chief technology officer''. I have a lot of respect for that experience but in no way does it qualify him to develop a market for a product attacking a market already occupied by some large international successfull competitors with years and years of experience.
Our CEO wasn’t smart enough (or was stubborn enough) to not accept that INVESTING IN MARKETING was effectively not an EXPENSE but an INVESTMENT, a concept she obviously did not understand even when failure was obvious.
The team she built shows she did not believe in the importance of Marketing.

Founders
Hamutal Yitzhak : Former Abbott Laboratories
Michael Azar : Chief Executive Officer at Materna Laboratories Ltd.
Uriel Kesler : Golden Heart FMCG Ltd. … Household, Appliances, Electrical and Electronic Goods

Management
Shay Shamir : worked as a Senior Auditor at Ernst & Young (Israel) Ltd
Dr. Fabiana Bar Yoseph : Director of Infant Nutrition Research & Development, Enzymotec Ltd
Renana Mizrahi : Hebrew University of Jerusalem B. Sc. Nut, Clinical Nutrition/Nutritionist
Avi Markus: innovator and leader in the Natural Food & Beverage space
Reuben Halevi : Chief Technology Officer at MIND C.T.I. Ltd. from 2018 to 2019.

Our CEO definitely was believing all along that : ‘’ If you have a great product it will sell automatically’’. More than 5 years later she still behaves as if she wasn’t able to accept she was wrong all along.
Marketing/sales go hand in hand with Product quality and one without the other leads to failure.
proven
This is more than an opinion ... it’s a proven fact and has been so for decades in many cases and industries, particularly in the case of startup like companies trying to penetrate new markets.